OrganiGram Holdings Inc. announced it has partnered with Medical Cannabis by Shoppers ('Shoppers') on Phase 2 of Shoppers' Pilot Program powered by software partner TruTrace Technologies Inc. (TruTrace). The program is designed to genetically finger-print all participating cannabis products, tracking them throughout the supply chain, from genome to patient, in order to provide real-time information about the composition of each cannabis product used by Medical Cannabis by Shoppers customers.?Organigram will provide cannabis products to Shoppers for use in the tracking program. Standardized and validated testing of medical cannabis, ensuring consistent quality and efficacy, are critical to the product's value as a viable treatment option.

Likewise, product information such as strain composition and potency can help healthcare practitioners and patients make more informed and confident decisions about their medical cannabis treatment regimens. Using Trutrace's StrainSecure system, the program collects plant testing data and performs genomic verification in plant batches which are then registered in a blockchain-enabled database for intellectual property protection and strain validation. All information gathered from the plants, including their molecular and chemical makeup, can be tracked via the technology.

As jurisdictions around the world have begun to legalize and adopt cannabis as a medical treatment, there has been an influx of?new breeders and growers and a profusion of new cannabis strains, each with a different representation of at least 500 known metabolites. Subtle changes in the chemical expression of various strains, whether by genetic structure or environmental conditions, may have significant clinical effects on the patients using this treatment option.?With so many strains available, and with relatively limited?information?on strain composition or genetic lineage and their relation to their chemical output, patients have?little?ability to control what they are?taking over time.